Tech Company Financing Transactions

Inspirna Funding Round

Sands Capital Management, Vivo Capital and Dreavent 6 participated in a $50 million Series D venture round for Inspirna. The round was announced by the company on 7/11/2022.

Transaction Overview

Company Name
Announced On
7/11/2022
Transaction Type
Venture Equity
Amount
$50,000,000
Round
Series D
Proceeds Purpose
Proceeds from the financing will support the clinical development of Inspirna's lead drug candidate RGX-202-01 ("RGX-202"), a first-in-class oral small molecule inhibitor of SLC6a8 to treat RAS mutant advanced colorectal cancer (CRC), and RGX-104, an oral small molecule activator of LXR/APOE to treat lung cancer and endometrial cancer.

Company Information

Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
310 East 67th St. 1-12
New York, NY 10065
USA
Email Address
Overview
Inspirna (formerly Rgenix) is developing first-in-class drugs that target key pathways in cancer progression. Using a discovery platform developed by Rgenix founding scientists at Rockefeller University, we have discovered several novel cancer targets that drive tumor growth and cancer progression.
Profile
Inspirna LinkedIn Company Profile
Social Media
Inspirna Company Twitter Account
Company News
Inspirna News
Facebook
Inspirna on Facebook
YouTube
Inspirna on YouTube

Management Team

Title
Name
Email & Social
Chief Executive Officer
Masoud Tavazoie
  Masoud Tavazoie LinkedIn Profile  Masoud Tavazoie Twitter Account  Masoud Tavazoie News  Masoud Tavazoie on Facebook
Chief Operating Officer
David Darst
  David Darst LinkedIn Profile  David Darst Twitter Account  David Darst News  David Darst on Facebook
Vice President
Stephen Wald
  Stephen Wald LinkedIn Profile  Stephen Wald Twitter Account  Stephen Wald News  Stephen Wald on Facebook
VP - Bus. Development
Foster Gonsalves
  Foster Gonsalves LinkedIn Profile  Foster Gonsalves Twitter Account  Foster Gonsalves News  Foster Gonsalves on Facebook
VP - Finance
Corey Sohmer
  Corey Sohmer LinkedIn Profile  Corey Sohmer Twitter Account  Corey Sohmer News  Corey Sohmer on Facebook
VP - R & D
Isabel Kurth
  Isabel Kurth LinkedIn Profile  Isabel Kurth Twitter Account  Isabel Kurth News  Isabel Kurth on Facebook
VP - Regulatory Affairs
Michael Szarek
  Michael Szarek LinkedIn Profile  Michael Szarek Twitter Account  Michael Szarek News  Michael Szarek on Facebook


 

 

Browse more venture capital transactions:

Prev: 7/11/2022: Halo Labs venture capital transaction
Next: 7/11/2022: Byzantion venture capital transaction

 

Share this article

 


Where The Data Comes From

We do our best to record every notable VC transaction. All VC database entries on this site are sourced from a variety of public sources. The data comes to us via our partnership with VentureDeal.com, an affiliated venture.

 


Additional Resources for Entrepreneurs

Lists of Venture Capital and Private Equity Firms

Franchise Opportunities

Contributors

Business Glossary